The stock of CTI BioPharma Corp (CTIC) closed the regular trading session at $3.95, gaining 17.21% from the previous day’s trading session. On the last check, the stock of CTIC remained bullish in the pre-market and gained 3.04% to $4.07. The firm provided an update about the approval of VONJO by the FDA. The company also filed form 8-K with the SEC on 2 March 2022.
News
On 28 February 2022, CTIC provided an update for the compliance of VONJO by the FDA. VONJO is a medicine that is used in the therapy of myelofibrosis and thrombocytopenia in adults. The firm made an announcement that the FDA has accepted the VONJA to treat the victim with a low count of platelets. The suggested dose of VONJO is 200 mg by mouth, two times a day. VONJO is the initial therapy that explicitly orates the necessities of victims with myelofibrosis. The sped-up endorsement depends on the adequacy outcome from the critical Phase 3 investigation of VONJO in victims with myelofibrosis. The common side effects include nausea, and diarrhea, while the serious side effects include heart failure and pneumonia.
The CEO of CTI BioPharma (CTIC), Adam R. Craig, stated that in the U.S., there are around 21,000 patients with myelofibrosis, 66% of which have cytopenia’s. He further added that we anticipate giving VONJO for cytopenic myelofibrosis treatment to the patients in 10 days. Moreover, Mr. Craig concluded that he is grateful to the CTI group for the persistent efforts, dedication, and emphasis on the requirements of victims.
About CTIC
CTI BioPharma Corp is a biopharmaceutical organization, which centers around the production, possession, and advertisation of novel designated treatments for blood cancers. Also, the firm has a market cap of $381.93 million with 96.69 million shares pending. CTIC has its base in Seattle, Washington, United States of America (USA).
